A5102768363- Protease and Inhibitor Mechanisms
- Blood properties and coagulation
- Mitochondrial Function and Pathology
- Blood Coagulation and Thrombosis Mechanisms
- Cancer and Skin Lesions
- Botulinum Toxin and Related Neurological Disorders
- Blood transfusion and management
- Endoplasmic Reticulum Stress and Disease
- RNA Interference and Gene Delivery
- Neurological and metabolic disorders
- Erythropoietin and Anemia Treatment
- Skin and Cellular Biology Research
- Neuropeptides and Animal Physiology
- Metabolism and Genetic Disorders
- Blood donation and transfusion practices
- ATP Synthase and ATPases Research
CHA Bundang Medical Center
2017-2018
CHA University
2017-2018
Soonchunhyang University
1992-1994
Soonchunhyang University Hospital
1992
Purpose. In this study, we investigated the effect of PGC1 α activators on mitochondrial fusion, fission, and autophagic quality control in renal tubular cells a diabetic environment vivo vitro. We also examined whether upregulation attenuates tubulopathy by normalizing homeostasis. Methods . HKC8 were subjected to high-glucose conditions (30 mM D-glucose). Diabetes was induced with streptozotocin (STZ, 50 mg/kg i.p. for 5 days) male C57/BL6J mice. AICAR or metformin used as activator....
We investigated the effects of chloroquine (CQ) and amodiaquine (AQ) on AMPK phosphorylation in renal tubular cells a diabetic environment vivo vitro. also examined whether CQ- or AQ-mediated activity restoration attenuated tubulopathy by normalizing mitochondrial fragmentation. Human proximal epithelial (HKC8) were incubated high-glucose conditions. Diabetes was induced with streptozotocin male C57/BL6J mice. Treatment CQ AQ abolished high-glucose-induced phospho-AMPK phosph-PGC1α...
Basal plasma tissue type plasminogen activator (t-PA) and inhibitor 1 (PAI-1) antigen levels were studied in 49 non-insulin dependent diabetic patients (23 men, 26 women: ages 51.3±14.9 years) 16 age matched non-diabetic subjects (9 7 49.8±12.2 as a control group. Compared to group, the had significantly higher mean t-PA (5.15±3.02 vs 3.20±2.30 ng/ml) PAI-1 (35.89±18.59 17.60±15.36 (p<0.05). Plasma level was not influenced by each treatment modality. There significant decrease of after...
It has been reported that a feedback circuit exists between erythropoietin (EPO) concentration and the degree of anemia even in end stage renal disease (ESRD), growing experience with subcutaneous EPO administration confirms only slight increases levels are required to correct anemia. Keeping mind these findings, if small portion reserved production could be reactivated ESRD, it might biologically significant vice-versa. From this viewpoint, is conceivable periodic long term transfusion...